Overriding drug and medical technology patents for pandemic recovery: A legitimate move for high-income countries, too
| Authors |
|
|---|---|
| Publication date | 04-2021 |
| Journal | BMJ Global Health |
| Article number | e005518 |
| Volume | Issue number | 6 | 4 |
| Number of pages | 4 |
| Organisations |
|
| Abstract |
Compulsory licenses are legal tools to override patent-protection on medicines and medical technologies. Compulsory licenses can help scale up the production and lower prices of patent-protected medicines while still accounting for the patent holder’s interests. Compulsory licensing is making a comeback in high-income countries as a negotiation strategy and a legal tool to remedy high prices and/or supply shortages of medicines and medical technologies. High-income countries that face potential legal hurdles (in world trade law and/or in the regulation of test data and market exclusivity) to effectively use compulsory licensing in the COVID-19 pandemic should consider taking measures now. |
| Document type | Comment/Letter to the editor |
| Language | English |
| Published at | https://doi.org/10.1136/bmjgh-2021-005518 |
| Other links | https://www.scopus.com/pages/publications/85103898285 |
| Downloads |
e005518.full
(Final published version)
|
| Permalink to this page | |
